Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
NEW YORK (Reuters Health) – Disease-free survival is not improved after resection of stage III colon cancer when cetuximab is added to chemotherapy with leucovorin, fluorouracil, and oxaliplatin…
NEW YORK (Reuters Health) – A Canadian study confirms an increased risk of uveitis and scleritis in first-time users of oral bisphosphonates. “Patients taking bisphosphonates must be familiar…
NEW YORK (Reuters Health) – Results of a meta-analysis show that in preterm infants with respiratory distress syndrome, early use of nasal intermittent positive pressure ventilation (NIPPV) compared…
NEW YORK (Reuters Health) – A guideline issued by the American Society of Clinical Oncology recommends that actual rather than an adjusted ideal body weight should be used…
NEW YORK (Reuters Health) – Reduced-dose chemotherapy in children with Down syndrome (DS) associated acute myeloid leukemia or myelodysplastic syndrome effectively maintains survival, researchers report in a March…
NEW YORK (Reuters Health) – Empiric therapy in extremely low birth weight (ELBW) infants with invasive Candida infections is associated with improved outcomes (less death and neurodevelopmental impairment),…
NEW YORK (Reuters Health) – Transplacental sotalol, alone or in combination with digoxin, is effective for the treatment of fetal supraventricular tachyarrhythmia (SVT) and atrial flutter, with rapid…
NEW YORK (Reuters Health) – An investigational formulation of azelastine and fluticasone (MP29-02) is more effective than either agent alone as intranasal therapy for moderate-to-severe seasonal allergic rhinitis…
NEW YORK (Reuters Health) – The investigational GLP-1 receptor antagonist lixisenatide significantly reduces postprandial glucose excursions and HbA1c in patients with type 2 diabetes who have not been…
NEW YORK (Reuters Health) – Results of two trials indicate that verteporfin photodynamic therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization…
